Imatinib Withdrawn Phase 2 Trials for Eosinophilia / Hypereosinophilic Syndromes Treatment

IndicationsStatusPurposePhase
WithdrawnTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00230334Phase II Gleevec Idiopathic Hypereosinophilic Syndrome